|
"liao bc"的相關文件
顯示項目 1-5 / 5 (共1頁)
1
每頁顯示[10|25|50]項目
| 國家衛生研究院 |
2025-02 |
Durvalumab, tremelimumab, and platinum chemotherapy in EGFR mutation–positive NSCLC: An open-label Phase 2 trial (ILLUMINATE)
|
Lee, CK;Liao, BC;Subramaniam, S;Chiu, CH;Mersiades, AJ;Ho, CC;Brown, C;Lai, CL;Hughes, BGM;Yang, TY;O'Byrne, K;Luo, YH;Yip, S;Ho, CL;Bray, V;Su, WC;Moore, M;Feng, WL;Bai, YY;Ford, K;Cummins, MM;Stockler, MR;Solomon, BJ;John, T;Chih-Hsin Yang, J |
| 國家衛生研究院 |
2025-01 |
Atezolizumab, bevacizumab, pemetrexed and platinum for EGFR-mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysis
|
Wu, SG;Ho, CC;Yang, JC;Yu, SH;Lin, YF;Lin, SC;Liao, BC;Yang, CY;Lin, YT;Yu, CJ;Chuang, YT;Liao, WY;Yap, KY;Kou, WS;Shih, JY |
| 國家衛生研究院 |
2024-09-30 |
Registry of genetic alterations of Taiwan non-small cell lung cancer by comprehensive next-generation sequencing: A real-world cohort study-Taiwan cooperative oncology group T1521
|
Liao, BC;Chiang, NJ;Chang, GC;Su, WC;Luo, YH;Chong, IW;Yang, TY;Lai, CL;Hsia, TC;Ho, CL;Lee, KY;Hsiao, CF;Ku, FC;Fang, WT;Chih-Hsin Yang, J |
| 國家衛生研究院 |
2023-11 |
The registry of genetic alterations of Taiwan NSCLC by comprehensive next-generation sequencing: A real-world cohort study - TCOG T1521 study
|
Liao, BC;Chiang, NJ;Chang, GC;Su, WC;Chong, IW;Yang, TY;Luo, YH;Lai, CL;Hsia, TC;Ho, CL;Lee, KY;Hsiao, CF;Yang, JCH |
| 國家衛生研究院 |
2023-11 |
ILLUMINATE: Efficacy and safety of durvalumab-tremelimumab and chemotherapy in EGFR mutant NSCLC following progression on EGFR inhibitors
|
Lee, C;Liao, BC;Subramaniam, S;Chiu, CH;Mersiades, A;Ho, CC;Brown, C;Lai, CL;Hughes, BGM;Yang, TY;O'Byrne, K;Luo, YH;Yip, S;Ho, CL;Bray, V;Su, WC;Moore, M;Feng, WL;Bai, YY;Stockler, M;Solomon, B;John, T;Yang, JCH |
顯示項目 1-5 / 5 (共1頁)
1
每頁顯示[10|25|50]項目
|
